Form 4: Ligand Pharmaceuticals CLO Andrew Reardon Executes Stock Option and Sells Shares

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, exercised stock options and sold shares on August 28, 2024.

Summary

• On August 28, 2024, Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, exercised non-qualified stock options to acquire 1,500 shares of common stock at a price of $52.27 per share.
• Simultaneously, Reardon sold 1,500 shares of common stock at a weighted-average price of $106.3937, with individual sales ranging from $106.3200 to $106.4700.
• Following these transactions, Reardon directly owns 22,534 shares of Ligand Pharmaceuticals common stock and holds options for 61,444 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives. It's common for executives to exercise stock options and sell shares for personal financial management.

Comparison to Industry Standards

• Executive compensation packages often include stock options as incentives.
• The vesting schedule of these options, such as the 12.5% initial vesting followed by monthly installments, is a standard practice.
• The sale of shares after exercising options is also a common practice for executives to realize the value of their compensation.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates